SPERO THERAPEUTICS INC's ticker is SPRO and the CUSIP is 84833T103. A total of 47 filers reported holding SPERO THERAPEUTICS INC in Q1 2023. The put-call ratio across all filers is - and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $183 | -16.4% | 151 | 0.0% | 0.00% | – |
| Q2 2023 | $219 | 0.0% | 151 | 0.0% | 0.00% | – |
| Q1 2023 | $219 | -16.1% | 151 | 0.0% | 0.00% | – |
| Q4 2022 | $261 | – | 151 | 0.0% | 0.00% | – |
| Q3 2022 | $0 | – | 151 | 0.0% | 0.00% | – |
| Q2 2022 | $0 | -100.0% | 151 | -86.9% | 0.00% | – |
| Q1 2022 | $10,000 | -44.4% | 1,151 | 0.0% | 0.00% | – |
| Q4 2021 | $18,000 | 0.0% | 1,151 | +15.1% | 0.00% | – |
| Q3 2021 | $18,000 | -57.1% | 1,000 | -66.7% | 0.00% | – |
| Q2 2021 | $42,000 | -4.5% | 3,000 | 0.0% | 0.00% | – |
| Q1 2021 | $44,000 | -24.1% | 3,000 | 0.0% | 0.00% | – |
| Q4 2020 | $58,000 | +75.8% | 3,000 | 0.0% | 0.00% | – |
| Q3 2020 | $33,000 | +135.7% | 3,000 | +200.0% | 0.00% | – |
| Q2 2020 | $14,000 | +250.0% | 1,000 | +100.0% | 0.00% | – |
| Q1 2020 | $4,000 | -20.0% | 500 | 0.0% | 0.00% | – |
| Q4 2019 | $5,000 | 0.0% | 500 | 0.0% | 0.00% | – |
| Q3 2019 | $5,000 | – | 500 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Atlas Venture Associates IX, LLC | 1,353,303 | $1,637,497 | 13.93% |
| Anson Funds Management LP | 4,159,572 | $5,033,082 | 1.01% |
| OUP Management Co., LLC | 249,070 | $301,375 | 0.68% |
| Atlas Venture Life Science Advisors, LLC | 1,013,438 | $1,226,260 | 0.19% |
| Murchinson Ltd. | 862,700 | $1,043,867 | 0.13% |
| Alphabet Inc. | 889,979 | $1,076,874 | 0.07% |
| AWM Investment Company, Inc. | 333,400 | $403,414 | 0.06% |
| DAFNA Capital Management LLC | 125,000 | $151,250 | 0.05% |
| Novo Holdings A/S | 468,902 | $567,371 | 0.04% |
| XTX Topco Ltd | 58,368 | $70,625 | 0.01% |